- DocuSign shares rise after earnings, and other movers
- Barron's DocuSign, Apple, Smartsheet, Guidewire Software, RH, and More Stock Market Movers
- U.S. stock futures lean higher after difficult week on Wall Street
- Barron's Banks Are Stuck in a Rut. A Buyout Wave Could Be Building.
- Barron's High-Quality Dividend Stocks Are on Sale. Now Is the Time to Buy.
- Barron's Why Walt Disney Could Cave First in Its Cable Standoff With Charter
- Barron's 5 Federal Deficit Myths, Explained
- Barron's Walgreens Is Looking for a New CEO. Why That Could Make the Stock a Winner.
- Barron's Active Funds Rocked August. Passive Is Grabbing the Year.
- Barron's It’s Not Just BlackRock. Exchanges Like Nasdaq Are Pushing into Crypto, Too.
- Open $189.00
- Day Range 170.87 - 189.66
- 52 Week Range 170.87 - 335.91
- Market Cap $13.5B
- Shares Outstanding 69.82M
- Public Float 69.54M
- Beta 0.96
- Rev. per Employee $563.50K
- P/E Ratio 199.12
- EPS $0.90
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 2.84M 08/15/23
- % of Float Shorted 4.09%
- Average Volume 889.13K
North America 9 Stocks That Could Be Dropped From the S&P 500
Shares of DexCom Inc. surged 8.1% to pace the S&P 500's premarket gainers, after the diabetes care company said it was not currently in "active discussions" regarding a merger. The stock has been dragged down over the pa...
Biotech and Pharma Insulet Stock Rises on Report of DexCom Acquisition Talks
Shares of Insulet Corp. gained 9.9% in premarket trading on Tuesday, the day after that the company is in talks to be acquired by Dexcom Inc. , citing anonymous sources. Dexcom's stock was down 7.1% before the market ope...
Insulet upgraded to buy from neutral at UBS
Insulet upgraded to outperform from perform at Oppenheimer
Biotech and Pharma Insulet Stock Rises as It Joins the Automated Insulin Device Competition
Insulet upgraded to buy from hold at Canaccord Genuity
Insulet Corp. price target raised to $220 from $195 at Stifel, hold stock rating
Insulet Corp. price target lifted to $249 from $200 at Raymond James, stock rating outperform
Insulet stock price target cut to $200 from $220 at Raymond James
Insulet downgraded to hold from buy at Canaccord Genuity
Insulet downgraded to neutral from buy at UBS
Insulet (PODD): A Hidden Gem in the Market? An In-Depth Analysis of Its Valuation
Insulet (PODD): A Hidden Gem Significantly Undervalued
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.